Moreover, once-daily treatment with CP-C27 led to marked suppression of tumor growth in SMARCA4/SMARCA2-deficient DMS114 and SS18–SSX fusion Fuji xenograft models (Fig. 6A–D), again with no adverse effect on the body weight of mice (Fig. 6E and F). This evidence concerns the gene SMARCA2 and neoplasm.